TWP
JAZZ icon

Triad Wealth Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Triad Wealth Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5
Closed -$534 – 483
2024
Q2 		$534 Buy
+5
New +$550 ﹤0.01% 916

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Triad Wealth Partners's JAZZ Position: Q3 2024 in Review

Triad Wealth Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2024, closing a stake of 5 shares — an estimated $534 sold.

Triad Wealth Partners first reported a position in JAZZ in Q2 2024 and held it in 1 quarter. The position peaked at $534 in Q2 2024. 477 funds tracked by Wall St. Rank hold JAZZ as of Q3 2024.

  • Triad Wealth Partners reported no remaining Jazz Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Triad Wealth Partners sold 5 Jazz Pharmaceuticals shares in Q3 2024, an estimated $534.
  • Triad Wealth Partners first reported a position in Jazz Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Triad Wealth Partners's Jazz Pharmaceuticals position peaked at $534 in Q2 2024.
  • 477 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2024.

Based on Triad Wealth Partners's 13F filing for Q3 2024, filed 21 Oct 2024.